{"id":"NCT05233566","sponsor":"Washington University School of Medicine","briefTitle":"Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial","officialTitle":"Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-04-25","primaryCompletion":"2023-03-08","completion":"2023-03-08","firstPosted":"2022-02-10","resultsPosted":"2024-04-10","lastUpdate":"2024-04-10"},"enrollment":32,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Postoperative Depression"],"interventions":[{"type":"DRUG","name":"Ketamine","otherNames":["Ketalar"]},{"type":"DRUG","name":"Normal saline","otherNames":[]}],"arms":[{"label":"Ketamine Arm","type":"EXPERIMENTAL"},{"label":"Control Arm","type":"PLACEBO_COMPARATOR"}],"summary":"This protocol describes a feasibility trial that will evaluate the feasibility of conducting a full-scale phase 3 trial testing the hypothesis that a postoperative sustained, low-dose ketamine infusion can prevent postoperative depressive symptoms when administered to a targeted population of neurosurgical patients with a history of depression.","primaryOutcome":{"measure":"Fraction of Approached Patients Who Enroll and Are Randomized","timeFrame":"3 days after surgery","effectByArm":[{"arm":"Protocol Version 1","deltaMin":1,"sd":null},{"arm":"Protocol Version 2","deltaMin":31,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["38179107","37483552"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":16},"commonTop":["Transient Ischemic Attack","Blisters around incision","Fever and chills","Nausea and vomiting"]}}